Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Pieris Pharmaceuticals, Inc. PIRS NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
36/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Pieris Pharmaceuticals, Inc. (PIRS) — Analyst outlook / Analyst consensus target is. Based on 2 analyst ratings, the consensus is bullish — 2 Buy.

PIRS Analyst Ratings

Buy
2
Ratings
2 Buy
Based on 2 analysts giving stock ratings to Pieris Pharmaceuticals, Inc. in the past 3 months
Rating breakdown
Buy
2 100%
100%
Buy
2 analysts
0%
Hold
0 analysts
0%
Sell
0 analysts

People Also View

TERN
TERN
Terns Pharmaceuticals, Inc.
$52.71
+0.06%
 CRVS
CRVS
Corvus Pharmaceuticals, Inc.
$15.11
-0.92%
 ADCT
ADCT
ADC Therapeutics S.A.
$4.37
+13.21%
 CKPT
CKPT
Checkpoint Therapeutics, Inc.
$4.26
+0.00%
 INZY
INZY
Inozyme Pharma, Inc.
$4.00
+0.25%
 AGEN
AGEN
Agenus Inc.
$4.83
+2.33%
 PDSB
PDSB
PDS Biotechnology Corporation
$1.36
+28.30%
 ADAP
ADAP
Adaptimmune Therapeutics plc
$0.05
-3.00%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message